Effect of Alirocumab on Postprandial Hyperlipemia in Patients With Type 2 Diabetes

NCT03344692 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

22

Enrollment

OTHER

Sponsor class

Conditions

Type2 Diabetes

Interventions

DRUG: Alirocumab
OTHER: Placebo

Sponsor

Nantes University Hospital

Collaborators

[object Object]